| Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death M Arrasate, S Mitra, ES Schweitzer, MR Segal, S Finkbeiner Nature 431 (7010), 805-810, 2004 | 2399 | 2004 |
| A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia SM O'Brien, N Lamanna, TJ Kipps, I Flinn, AD Zelenetz, JA Burger, ... Blood 126 (25), 2686-2694, 2015 | 300 | 2015 |
| Identifying polyglutamine protein species in situ that best predict neurodegeneration J Miller, M Arrasate, E Brooks, CP Libeu, J Legleiter, D Hatters, J Curtis, ... Nature chemical biology 7 (12), 925-934, 2011 | 232 | 2011 |
| Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia JP Sharman, SE Coutre, RR Furman, BD Cheson, JM Pagel, P Hillmen, ... Journal of Clinical Oncology 37 (16), 1391-1402, 2019 | 221 | 2019 |
| AMPA receptors regulate transcription of the plasticity-related immediate-early gene Arc VR Rao, SA Pintchovski, J Chin, CL Peebles, S Mitra, S Finkbeiner Nature neuroscience 9 (7), 887-895, 2006 | 217 | 2006 |
| Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease … J Miller, M Arrasate, BA Shaby, S Mitra, E Masliah, S Finkbeiner Journal of Neuroscience 30 (31), 10541-10550, 2010 | 194 | 2010 |
| Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease S Mitra, AS Tsvetkov, S Finkbeiner Journal of Biological Chemistry 284 (7), 4398-4403, 2009 | 115 | 2009 |
| The ubiquitin-proteasome pathway in Huntington's disease S Mitra, S Finkbeiner The Scientific World Journal 8, 421-433, 2008 | 88 | 2008 |
| Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric … ZA Wainberg, PC Enzinger, YK Kang, K Yamaguchi, S Qin, KW Lee, ... Journal of Clinical Oncology 39 (3_suppl), 160-160, 2021 | 80 | 2021 |
| Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure C Peters-Libeu, J Miller, E Rutenber, Y Newhouse, P Krishnan, K Cheung, ... Journal of Molecular Biology 421 (4), 587-600, 2012 | 69 | 2012 |
| Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic LeukemiaPhase Ib Study of Tirabrutinib Combinations in CLL AV Danilov, C Herbaux, HS Walter, P Hillmen, SA Rule, EA Kio, L Karlin, ... Clinical Cancer Research 26 (12), 2810-2818, 2020 | 59 | 2020 |
| Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059 HS Walter, S Jayne, SA Rule, G Cartron, F Morschhauser, S Macip, ... Blood 129 (20), 2808-2810, 2017 | 59 | 2017 |
| Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma AK Gopal, MA Fanale, CH Moskowitz, AR Shustov, S Mitra, W Ye, ... Annals of Oncology 28 (5), 1057-1063, 2017 | 53 | 2017 |
| Protein turnover and inclusion body formation S Mitra, AS Tsvetkov, S Finkbeiner Autophagy 5 (7), 1037-1038, 2009 | 43 | 2009 |
| FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal … DVT Catenacci, YK Kang, A Saeed, K Yamaguchi, S Qin, KW Lee, IH Kim, ... Journal of Clinical Oncology 39 (15_suppl), 4010-4010, 2021 | 32 | 2021 |
| Protein turnover differences between neurons and other cells AS Tsvetkov, S Mitra, S Finkbeiner Autophagy 5 (7), 1037, 2009 | 30 | 2009 |
| Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC) MA Tejani, E Cheung, PD Eisenberg, AJ Scott, AA Tesfaye, L Dreiling, ... J Clin Oncol 37 (4), 91, 2019 | 14 | 2019 |
| Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor … JP Sharman, AR Shustov, MR Smith, CT Hagenstad, KS Kolibaba, ... Blood 128 (22), 3225-3225, 2016 | 9 | 2016 |
| Clinical activity of entospletinib (GS-9973), a selective SYK inhibitor, in patients with CLL previously treated with an inhibitor of B-cell receptor pathway signaling JP Sharman, AR Shustov, MR Smith, TE Boyd, C Hagenstad, KS Kolibaba, ... Blood 126 (23), 1744-1744, 2015 | 3 | 2015 |
| Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia HS Walter, S Jayne, SA Rule, G Cartron, F Morschhauser, C Fegan, ... Blood 128 (22), 3233-3233, 2016 | 2 | 2016 |
